RxDoctor Payments Data

Mark Voyack, PA

Surgical · Allentown, PANPI 1538755277

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,381 of the $5,131 with a category attached, or 85.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,772, 2.0 times the $877 reported in 2021. Among surgical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,131in general payments, 2019–2025

Across 122 payments — averaging $42.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$972
  • Johnson & Johnson$891
  • Intuitive Surgical$766
  • AstraZeneca$397
  • Pfizer$287
  • Astellas Pharma US Inc$251
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$74915%
  • Food & beverage$4,38185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,131 in reported general payments places this provider in the 95th percentile of 626 surgical providers in Pennsylvania.

See all surgical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$161,484
Medicare patients
726
Services billed
4,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide23$300,470
MyrbetriqMirabegron18$16,018
Tamsulosin Hcl630$12,210
Silodosin35$2,694
Solifenacin Succinate32$2,597
Finasteride125$2,046
Trospium Chloride29$1,251
Bicalutamide41$1,031
CefuroximeCefuroxime Axetil141$783
Alfuzosin Hcl ErAlfuzosin Hcl43$733
Oxybutynin Chloride ErOxybutynin Chloride49$732
Oxybutynin Chloride19$401
Cephalexin67$326
Doxycycline Hyclate13$129
Ketorolac Tromethamine11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$251$316,48841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 surgical providers in Pennsylvania.

Other surgical in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →